- Home
- SABR vs ELVN Comparison
SABR vs ELVN Comparison
Compare SABR & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABR
- ELVN
- Stock Information
- Founded
- SABR 2006
- ELVN 2016
- Country
- SABR United States
- ELVN United States
- Employees
- SABR N/A
- ELVN N/A
- Industry
- SABR Computer Software: Programming Data Processing
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- SABR Technology
- ELVN Health Care
- Exchange
- SABR Nasdaq
- ELVN Nasdaq
- Market Cap
- SABR 1.3B
- ELVN 1.1B
- IPO Year
- SABR 2014
- ELVN 2020
- Fundamental
- Price
- SABR $2.03
- ELVN $16.53
- Analyst Decision
- SABR Hold
- ELVN Strong Buy
- Analyst Count
- SABR 4
- ELVN 4
- Target Price
- SABR $4.15
- ELVN $39.25
- AVG Volume (30 Days)
- SABR 8.7M
- ELVN 359.8K
- Earning Date
- SABR 05-01-2025
- ELVN 05-13-2025
- Dividend Yield
- SABR N/A
- ELVN N/A
- EPS Growth
- SABR N/A
- ELVN N/A
- EPS
- SABR N/A
- ELVN N/A
- Revenue
- SABR $3,029,565,000.00
- ELVN N/A
- Revenue This Year
- SABR $9.49
- ELVN N/A
- Revenue Next Year
- SABR $5.52
- ELVN N/A
- P/E Ratio
- SABR N/A
- ELVN N/A
- Revenue Growth
- SABR 4.19
- ELVN N/A
- 52 Week Low
- SABR $1.93
- ELVN $13.30
- 52 Week High
- SABR $4.63
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- SABR 31.74
- ELVN 40.34
- Support Level
- SABR $1.99
- ELVN $15.49
- Resistance Level
- SABR $2.41
- ELVN $18.14
- Average True Range (ATR)
- SABR 0.24
- ELVN 1.93
- MACD
- SABR -0.02
- ELVN -0.17
- Stochastic Oscillator
- SABR 9.43
- ELVN 41.09
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2023 revenue, split between distribution (78% of segment sales) and airline IT solutions (22%) revenue. The company also has a growing hotel IT solutions division (9% of revenue). Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.